Madrigal Pharmaceuticals in Conshohocken Reports $14.6 Million in Sales from Groundbreaking NASH Drug Rezdiffra

By

Rezdiffra pills
Image via Rezdiffra.
Conshohocken-based Madrigal Pharmaceuticals generated $14.6 million in sales from Rezdiffra during the second quarter.

Conshohocken-based Madrigal Pharmaceuticals generated $14.6 million in sales from Rezdiffra, its first and flagship product, during the second quarter of 2024, writes John George for the Philadelphia Business Journal.

Rezdiffra was granted Food and Drug Administration approval in March, and became the first drug cleared to treat nonalcoholic steatohepatitis, or NASH. The product, which hit the market on April 9, already has over 2,000 patients using it. The treatment has a list price of $47,400 per year.

The company has assembled a sales team of between 150 and 200 for Rezdiffra.

“We’re off to a strong start and are encouraged by the high enthusiasm and early demand from physicians and patients, as well as the favorable coverage from payers,” said Bill Sibold, Madrigal Pharmaceuticals CEO. “The urgent unmet need in NASH, which is the leading cause of liver transplant among women in the U.S., is driving the strong reception.”

NASH is a fatty liver disease that is characterized by inflammation of the liver. According to the American Liver Foundation, around five percent of adults in the United States have NASH.

Read more about Madrigal Pharmaceuticals in the Philadelphia Business Journal.


Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH

Stay Connected, Stay Informed

Subscribe for great stories in your community!

"*" indicates required fields

This field is hidden when viewing the form
MT Yes
Advertisement